Curated CRC research, accessible, accurate, actionable

The CRC Digest

Tuesday, October 06, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ▪ SCREENING

  Interventions to improve colonoscopy follow-up after abnormal stool tests show promise

  A systematic review and meta-analysis found that follow-up colonoscopy screening rates after abnormal FIT or FOBT remain suboptimal, prompting evaluation of targeted interventions to improve completion. (JAMA Intern Med)

• ♥ LIVING WITH CRC

  Short-course vs long-course radiation: quality of life outcomes compared in rectal cancer

  Researchers assessed longitudinal quality of life and functional outcomes using the EORTC QLQ-CR29 in rectal cancer patients treated with short-course radiation (25 Gy/5 fractions) versus long-course chemoradiation (50-50.4 Gy/25-28 fractions). (Int J Radiat Oncol Biol Phys)

• ◇ RESEARCH

  Blocking PLA1A enzyme may enhance chemoimmunotherapy by reducing immunosuppressive macrophages

  Single-cell RNA sequencing of paired samples before and after neoadjuvant chemotherapy revealed that non-responders had increased M2-like macrophage infiltration linked to elevated PLA1A. (Cancer Res)

• ♥ LIVING WITH CRC

  Malnutrition identified as independent risk factor for cardiovascular toxicity from FOLFOX/XELOX chemotherapy

  A retrospective cohort study of 320 CRC patients found that malnutrition, present in up to 60% of post-surgical patients, may amplify cardiovascular toxicity from fluoropyrimidine- and oxaliplatin-based regimens through systemic inflammation and pharmacokinetic alterations. (Front Cardiovasc Med)

This week's research spans screening follow-up strategies, treatment-related quality of life, immune microenvironment mechanisms, and risk stratification in younger adults.